Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP005: Long-term efficacy and safety of mirikizumab treatment for Crohn’s Disease: Results from the VIVID-2 open-label extension studyECCO'25 Berlin
Year: 2025
Authors: Vermeire, Séverine
DOP012: Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical studyECCO'25 Berlin
Year: 2025
Authors: Schreieck, Amelie
DOP020: Baseline Microbiota and Differences in Donor-Recipient Richness as Determinants of Fecal Microbiota Transplantation Efficacy in Ulcerative ColitisECCO'25 Berlin
Year: 2025
Authors: Deleu, Sara
DOP031: Anti-IL-7 receptor plus anti-IL12/23 combination induces complete histological normalization in chronic colitisECCO'25 Berlin
Year: 2025
Authors: Poirier, Nicolas
DOP033: Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel DiseaseECCO'25 Berlin
Year: 2025
Authors: Schreiber, Taylor
DOP046: Effectiveness and Safety of Mirikizumab after switching from Ustekinumab in patients with moderate to severe Crohn’s disease: results from a long-term extension studyECCO'25 Berlin
Year: 2025
Authors: D'Haens, Geert
DOP048: Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QDECCO'25 Berlin
Year: 2025
Authors: Danese, Silvio
DOP051: Upadacitinib for induction of remission in pediatric Ulcerative Colitis: An international multi‑center studyECCO'25 Berlin
Year: 2025
Authors: Yerushalmy-Feler, Anat
DOP058: Efficacy and Safety of Vedolizumab Combined with Upadacitinib in Moderate-to-Severe Ulcerative Colitis: A Multicenter, Prospective, Randomized Controlled TrialECCO'25 Berlin
Year: 2025
Authors: Zhi, Min
DOP060: Early disease efficacy of guselkumab therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studiesECCO'25 Berlin
Year: 2025
Authors: D'Haens, Geert
DOP061: RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active ulcerative colitis – Findings from the phase IIb TUSCANY-2 trialECCO'25 Berlin
Year: 2025
Authors: Yarur, Andres
DOP066: Temperature-triggered in situ forming lipidic gel for local treatment of ulcerative colitisECCO'25 Berlin
Year: 2025
Authors: Aleandri, Simone
DOP068: Vedolizumab counteracts Parkinson’s disease-related brain pathology driven by gut-primed IBD T cellsECCO'25 Berlin
Year: 2025
Authors: Gerasimova, Elizaveta
DOP069: Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with ulcerative colitisECCO'25 Berlin
Year: 2025
Authors: Verstockt, Bram
DOP097: Emulsifier restriction is an effective therapy for active Crohn’s disease: the ADDapt trial - a multi-centre, randomised, double-blind, placebo-controlled, re-supplementation trial in 154 patientsECCO'25 Berlin
Year: 2025
Authors: Bancil, Aaron
DOP100: RXC008, a first-in-class gastrointestinal restricted pan-ROCK inhibitor developed for treatment of intestinal fibrosis shows GI restriction and tolerability: Results from the phase 1 program in healthy participants.ECCO'25 Berlin
Year: 2025
Authors: Rieder, Florian
DOP113: Residual TYK2 signalling is associated with non-response to vedolizumab and systemic TNF inhibitors among patients with ulcerative colitis: post hoc analyses of mucosal transcriptome dataECCO'25 Berlin
Year: 2025
Authors: Paraskevopoulou, Maria
DOP114: LDN-071, the novel amino acid-based PAI-1 inhibitor, significantly reduces the severity of acute and chronic inflammation in colitis modelsECCO'25 Berlin
Year: 2025
Authors: Jójárt, Boldizsár
DOP116: Preclinical characterization of IMU-856, an orally available epigenetic modulator of gut barrier function and regenerationECCO'25 Berlin
Year: 2025
Authors: Wirth, Martina
NSC08: UC Management16th N-ECCO School - Session 2: Case studies - Disease management
Year: 2025
Authors: Noor, Nurulamin